China Pharmaceutical Distribution Industry Report, 2017-2021
  • Sep.2017
  • Hard Copy
  • USD $2,800
  • Pages:100
  • Single User License
    (PDF Unprintable)       
  • USD $2,600
  • Code: ZLC056
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,000
  • Hard Copy + Single User License
  • USD $3,000
      

The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit RMB2.9784 trillion in 2021 at a growth rate of 10% over the next five years driven by favorable policies and downstream demand.

Western medicine sales dominate the Chinese pharmaceutical distribution market, accounting for 74.4% in 2016; East China and Central South China hold relatively higher percentages, up to 61.1% together in 2016.

The country has developed a competitive landscape where there are national pharmaceutical distributors represented by China National Pharmaceutical Group Corporation (Sinopharm), China Resources Pharmaceutical Commercial Group, Shanghai Pharmaceuticals and Jointown Pharmaceutical Group and regional ones represented by NanJing Pharmaceutical, Guangzhou Pharmaceuticals, Chongqing Pharmaceutical, Huadong Medicine, Sichuan Kelun, Zhejiang Int'l, Realcan Pharmaceutical, Guangxi Liuzhou Pharmaceutical Co., Ltd. and Luyan Pharma Co., Ltd. which compete with each other.

By the end of Nov 2016, there were 12,975 pharmaceutical wholesalers nationwide which competed fiercely in a lowly concentrated market. Top3 champions seized only a combined 28.7% share of the market in 2016.

医药分销EN_副本.png


As medical reform policies are implemented and consolidation in pharmaceutical wholesale industry accelerates, the Chinese pharmaceutical distribution market will show trends as follows: 1) pharmaceutical E-commerce will become an important model; 2) pharmaceutical supply chain management will be upgraded; 3) capital market will play a bigger role in integration of enterprises; 4) cross-border integration of pharmaceuticals and E-commerce will continue; 5) stiffer competition will improve market concentration; 6) Wholesale-retail integration will spur industry consolidation.

China Pharmaceutical Distribution Industry Report, 2017-2021 highlights the following:
20120114.gifPharmaceutical distribution industry in China (development environment, status quo, market size/structure, competitive landscape, development trends, etc.);
20120114.gifChinese pharmaceutical retail market (market size, quantity, top100 pharmacy chains, online pharmacy, independent pharmacy, etc.);
20120114.gif15 Chinese pharmaceutical distributors (profile, operation, revenue structure, gross margin, development prospects, etc.)

1. Overview of Pharmaceutical Distribution Industry
1.1 Definition
1.2 Industry Chain
1.3 Strength and Weakness of Pharmaceutical Chain Enterprises
1.3.1 Strength of Pharmaceutical Chain Enterprises
1.3.2 Weakness of Pharmaceutical Chain Enterprises

2 Pharmaceutical Distribution Industry in China
2.1 Development Environment
2.1.1 Policy
2.1.2 Economy
2.1.3 Medical Institution 
2.1.4 Health Expenditure
2.1.5 Aging
2.1.6 Per Capita Disposable Income
2.2 Status Quo
2.3 Market Size
2.4 Market Structure
2.5 Competitive Landscape
2.6 Development Trends
2.6.1 Pharmaceutical E-commerce Becomes an Important Model
2.6.2 Operating Efficiency and Service Functions Gets Improved Constantly
2.6.3 Capital Market Plays a Bigger Role in Integration of Enterprises
2.6.4 Pharmaceutical Supply-chain Management Services Are Upgraded Rapidly
2.6.5 Cross-border Integration of Pharmaceuticals and E-commerce Continues
2.6.6 Stiffer Competition Improves Market Concentration
2.6.7 Growing Trend towards Regionalization
2.6.8 Wholesale-retail Integration Spurs Industry Consolidation

3 Chinese Drug Retail Market
3.1 Market Size
3.2 Quantity
3.3 Top100 Pharmacy Chains
3.3.1 Revenue
3.3.2 Branch
3.4 Online Pharmacy
3.5 Independent Pharmacy

4 Major Enterprises
4.1 China National Accord Medicines Corporation Ltd.
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Major Customers
4.1.5 Pharmaceutical Distribution Business
4.1.6 Development Forecast
4.2 Nanjing Pharmaceutical Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Development Forecast
4.3 Shanghai No.1 Pharmacy Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Development Forecast
4.4 China National Medicines Corporation Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Development Forecast
4.5 Huadong Medicine Co., Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Major Customers
4.5.6 Development Forecast
4.6 Cachet Pharmaceutical Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Major Customers
4.6.6 Development Forecast
4.7 Jointown Pharmaceutical Group Co., Ltd.
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 Major Customers
4.7.6 Development Forecast
4.8 Realcan Pharmaceutical Co., Ltd.
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 Development Forecast
4.9 Shanghai Pharmaceuticals Holding Co., Ltd.
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Gross Margin
4.9.5 Development Forecast
4.10 Zhejiang Int'l Group Co., Ltd.
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Gross Margin
4.10.5 Development Forecast
4.11 Zhejiang Zhenyuan Share Co., Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Revenue Structure
4.11.4 Gross Margin
4.11.5 Development Forecast
4.12 China Meheco Co., Ltd.
4.12.1 Profile
4.12.2 Operation
4.12.3 Revenue Structure
4.12.4 Gross Margin
4.12.5 Development Forecast
4.13 Charmacy Pharmaceutical Co., Ltd.
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 Development Forecast
4.14 Luyan Pharma Co., Ltd.
4.14.1 Profile
4.14.2 Operation
4.14.3 Revenue Structure
4.14.4 Gross Margin
4.14.5 Development Forecast
4.15 China Resources Pharmaceutical Group Limited
4.15.1 Profile
4.15.2 Operation
4.15.3 Revenue Structure
4.15.4 Gross Margin
4.15.5 Development Forecast
China Pharmaceutical Distribution Channel
Difference between Pure Marketing and Allocation in China’s Pharmaceutical Distribution
China’s Laws and Regulations on Pharmaceutical Distribution Industry, 2001-2017
China’s GDP, 2012-2017
Number of Medical and Healthcare Institutions in China, 2015-2017
Number of Hospitals in China, 2009-2017
Number of Hospitals in China by Economic Type, 2009-2017
Health Expenditure in China, 2010-2016
Health Expenditure in China, 2016-2021E
Population Aged over 60 in China, 2009-2021E
Residents’ Per-capita Disposable Income and YoY Growth in China, 2011-2016
Business Models of China Pharmaceutical Distribution Industry by Market
M&A Cases in China Pharmaceutical Distribution Industry, 2016-2017
Pharmaceutical Distribution Market Size and YoY Growth in China, 2006-2016
Pharmaceutical Distribution Market Size and YoY Growth in China, 2016-2021E
Pharmaceutical Distribution Sales Structure in China by Type, 2016
Pharmaceutical Distribution Sales Structure in China by Region, 2016
Pharmaceutical Distribution Revenue in China by Region, 2016
TOP20 Pharmaceutical Distribution Enterprises in China by Operating Revenue, 2016
Representative Pharmaceutical Distribution Enterprises in China by Regional Market
Drug Retail Market Size and YoY Growth in China, 2012-2016
Drug Retail Market Size and YoY Growth in China, 2016-2021E
Number of Drug Retail Chains in China, 2012-2016
Drug Retail Chains in China by Number of Stores, 2012-2016    
Number of Independent Retail Drugstores in China, 2012-2016
TOP100 Pharmacy Chains in China by Total Revenue, 2016
TOP100 Pharmacy Chains in China by Number of Pharmacies, 2016
TOP20 Online Pharmacies in China by Revenue, 2016
TOP30 Independent Pharmacies in China by Revenue, 2016
Revenue and Net Income of China National Accord Medicines, 2013-2017
Revenue Breakdown of China National Accord Medicines by Business, 2015-2016
Revenue Breakdown of China National Accord Medicines by Region, 2015-2016
China National Accord Medicines’ Revenue from Top 5 Clients, 2014-2016
Revenue and Net Income of China National Accord Medicines, 2016-2021E
Revenue and Net Income of Nanjing Pharmaceutical, 2013-2017
Revenue Breakdown of Nanjing Pharmaceutical by Business, 2015-2016
Revenue Breakdown of Nanjing Pharmaceutical by Region, 2014-2016
Revenue Structure of Nanjing Pharmaceutical by Region, 2014-2016
Gross Margin of Nanjing Pharmaceutical by Business, 2014-2016
Revenue and Net Income of Nanjing Pharmaceutical, 2016-2021E
Revenue and Net Income of Shanghai No.1 Pharmacy, 2013-2017
Revenue Breakdown of Shanghai No.1 Pharmacy by Business, 2014-2016
Revenue Structure of Shanghai No.1 Pharmacy by Business, 2014-2016
Gross Margin of Shanghai No.1 Pharmacy, 2014-2016
Gross Margin of Shanghai No.1 Pharmacy by Business, 2014-2016
Revenue and Net Income of Shanghai No.1 Pharmacy, 2016-2021E
Revenue and Net Income of China National Medicines, 2013-2017
Revenue Breakdown of China National Medicines by Business, 2014-2016
Revenue Structure of China National Medicines by Business, 2014-2016
Revenue Breakdown of China National Medicines by Region, 2014-2016
Revenue Structure of China National Medicines by Region, 2014-2016
Gross Margin of China National Medicines, 2014-2016
Gross Margin of China National Medicines by Business, 2014-2016
Revenue and Net Income of China National Medicines, 2016-2021E
Revenue and Net Income of Huadong Medicine, 2013-2017
Revenue Breakdown of Huadong Medicine by Sector, 2014-2016
Revenue Structure of Huadong Medicine by Sector, 2014-2016 
Gross Margin of Huadong Medicine by Sector, 2014-2016
Huadong Medicine’s Revenue from Top5 Clients and % of Total Revenue, 2014-2016
Revenue and Net Income of Huadong Medicine, 2016-2021E 
Revenue and Net Income of Cachet Pharmaceutical, 2013-2017
Revenue Breakdown of Cachet Pharmaceutical by Business, 2014-2017
Revenue Structure of Cachet Pharmaceutical by Business, 2014-2017 
Revenue Breakdown of Cachet Pharmaceutical by Region, 2014-2017
Revenue Structure of Cachet Pharmaceutical by Region, 2014-2017
Gross Margin of Cachet Pharmaceutical’s Pharmaceutical Wholesale Business, 2014-2017
Cachet Pharmaceutical’s Revenue from Top5 Clients and % of Total Revenue, 2014-2017
Cachet Pharmaceutical’s Investment Projects with Raised Funds, 2016
Revenue and Net Income of Cachet Pharmaceutical, 2016-2021E
Revenue and Net Income of Jointown Pharmaceutical Group, 2013-2017
Revenue Breakdown of Jointown Pharmaceutical Group by Business, 2014-2016
Revenue Structure of Jointown Pharmaceutical Group by Business, 2014-2016
Gross Margin of Jointown Pharmaceutical Group by Business, 2014-2016
Jointown Pharmaceutical Group’s Revenue from Top5 Clients and % of Total Revenue, 2014-2016
Revenue and Net Income of Jointown Pharmaceutical Group, 2016-2021E
Revenue and Net Income of Realcan Pharmaceutical, 2013-2017
Revenue Breakdown of Realcan Pharmaceutical by Business, 2014-2016
Revenue Structure of Realcan Pharmaceutical by Business, 2014-2016
Gross Margin of Realcan Pharmaceutical by Business, 2014-2016 
Revenue and Net Income of Realcan Pharmaceutical, 2016-2021E
Revenue and Net Income of Shanghai Pharmaceuticals Holding, 2013-2017
Revenue Breakdown of Shanghai Pharmaceuticals Holding by Business, 2014-2016
Revenue Structure of Shanghai Pharmaceuticals Holding by Business, 2014-2016
Revenue Breakdown of Shanghai Pharmaceuticals Holding by Region, 2014-2016
Revenue Structure of Shanghai Pharmaceuticals Holding by Region, 2014-2016
Gross Margin of Shanghai Pharmaceuticals Holding by Business, 2014-2016
Revenue and Net Income of Shanghai Pharmaceuticals Holding, 2016-2021E
Revenue and Net Income of Zhejiang Int'l Group, 2013-2017
Revenue Breakdown of Zhejiang Int'l Group by Business, 2014-2016
Gross Margin of Zhejiang Int'l Group’s Pharmaceutical Sales Business, 2014-2017
Revenue and Net Income of Zhejiang Int'l Group, 2016-2021E
Revenue and Net Income of Zhejiang Zhenyuan, 2013-2017
Revenue Breakdown of Zhejiang Zhenyuan by Business, 2014-2017
Revenue Structure of Zhejiang Zhenyuan by Business, 2014-2017
Gross Margin of Zhejiang Zhenyuan by Business, 2014-2017
Revenue and Net Income of Zhejiang Zhenyuan, 2016-2021E
Revenue and Net Income of China Meheco, 2013-2017
Revenue Breakdown of China Meheco by Business, 2014-2017
Revenue Structure of China Meheco by Business, 2014-2017
Gross Margin of China Meheco by Business, 2014-2017
Revenue and Net Income of China Meheco, 2016-2021E
Revenue and Net Income of Charmacy Pharmaceutical, 2013-2017
Revenue Breakdown of Charmacy Pharmaceutical by Product/Client, 2013-2017
Revenue Structure of Charmacy Pharmaceutical by Product/Client, 2013-2017
Gross Margin of Charmacy Pharmaceutical, 2013-2017
Charmacy Pharmaceutical’s Distribution Network in Guangdong as of June 2017
Revenue and Net Income of Charmacy Pharmaceutical, 2016-2021E
Luyan Pharma’s Investment Projects with Raised Funds by Initial Public Offerings 
Revenue and Net Income of Luyan Pharma, 2013-2017
Revenue Breakdown of Luyan Pharma by Business, 2014-2017
Revenue Structure of Luyan Pharma by Business, 2014-2017 
Gross Margin of Luyan Pharma’s Pharmaceutical Wholesale Business, 2014-2017
Revenue and Net Income of Luyan Pharma, 2016-2021E
Revenue and Net Income of China Resources Pharmaceutical Group, 2013-2017
Revenue Breakdown of China Resources Pharmaceutical Group by Business, 2013-2017
Revenue Structure of China Resources Pharmaceutical Group by Business, 2013-2017
Gross Margin of China Resources Pharmaceutical Group, 2013-2017
Distribution Network Layout of China Resources Pharmaceutical Group
Revenue and Net Income of China Resources Pharmaceutical Group, 2016-2021E

China Pharmaceutical Distribution Industry Report, 2017-2021

The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit...

China Blood Product Industry Report, 2017-2021

China’s blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 201...

China Pharmaceutical Packaging Industry Report, 2016-2021

Under the impetus of the fast-growing downstream pharmaceutical industry, Chinese pharmaceutical packaging market size increased year by year at the CAGR of 11.2% during 2010-2016. From 2017 to 2021, ...

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Ch...

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Monoclonal Antibody Industry Report, 2013-2017

Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the m...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

China Pharmaceutical Equipment Industry Report, 2012-2015

Driven by the new GMP certification as well as the brisk downstream demand, China pharmaceutical equipment industry has seen steady progress in sales volume and technological content of products over ...

China Genetic Engineering Drug Industry Report, 2011-2012

China gets a late start in developing genetic engineering drug industry, but has achieved leapfrog advance. At present, China has at least one hundred enterprises involved in genetic engineering drugs...

China Animal Vaccine Industry Report, 2011-2012

Along with the frequent outbreaks of animal epidemics, the government’s increasing investment in epidemic prevention and the implementation of compulsory immunization system, Chinese animal vaccine ma...

China Human Vaccine Industry Report, 2011-2012

After decades of development, China has become one of the major producer and consumers of human vaccine around the world. In 2011, human vaccine manufacturers numbered 38 in China and the lot release ...

China Chemical Pharmaceutical Industry Report, 2011

In Jan.-Aug., 2011, the gross industrial output value of Chinese chemical pharmaceutical industry surged by 24.54% YoY to RMB460.531 billion, up 2.67 percentage points over the same period of last yea...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统